Effect of vitamin D3 on serum lipid profile and HbA1c levels in type 2 diabetes mellitus: a randomized controlled study
The purpose of this study was to review the effect of vitamin D3 (VD3) supplementation on glycemic control and lipid profile in patients with Type 2 Diabetes Mellitus (T2DM). A total of 68 T2DM patients with hemoglobin A1C (HbA1c)>6.5 and 25(OH) VD3<30 ng/ml were included in the study. They were randomly divided into two groups: placebo (n=34), and VD3 (n=34). Patients received weekly (VD3 (50,000 IU)/placebo) for 8 weeks. HbA1c levels, FBS and lipid profiles were assessed at baseline and after 8 weeks. A number of 62 people included VD3 (n=30) and placebo (n=32) completed the study, 25(OH) VD3 serum increased significantly after 8 weeks in the VD3 group compared to the placebo group (P<0.001). HbA1c levels, slightly higher, had decreased in the VD3 group compared to the placebo group (-0.35±1.2 vs. -0.13±1.50%, P=0.50). FBS levels slightly decreased in the VD3 group, compared to the placebo group (-6.93±39.57 vs. 5.53±42.21 mg/dl, P=0.07). In contrast to the slight decrease in total cholesterol (TC) and LDL levels in the VD3 group, was observed a slight increase in TC and LDL levels in the placebo group, and this increase was almost significant for TC (-1.26±36.72 vs. 14.65±41.56 mg/dl, P=0.05). The effect of VD3 may increase in improving hyperglycemia and lipid profile levels with increasing intervention time and sample size.